PIK3CG and cancer: Together, this data demonstrates the potential to use information about the underlying molecular biology of the cancer subtypes to make informed decisions about clinical management strategies and suggests that HDAC and PIK3/mTOR inhibitors, in combination with current treatment regimes, may provide a novel treatment tailored to lung SqCC.